close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

141.54 +0.08 (+0.06%)
Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
News headline image
Avidity Biosciences Soars After $72 Per Share Novartis Takeover ↗
Avidity Biosciences (RNA) to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral. 
Via Benzinga
News headline image
Qualcomm, Tesla, Intellia Therapeutics, Avidity Biosciences, Dyne Therapeutics: Stocks Making The Biggest Moves Today ↗
Qualcomm shares were up more than 11% in Monday’s midday session after the company unveiled two AI accelerator chips. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis ↗
Via Stocktwits
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
Via Investor Brand Network
News headline image
What to Expect from Novartis's Earnings ↗
 
Via Benzinga
News headline image
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NYSE:NVS),(NASDAQ:BCAX),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal ↗
Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash. 
Via Benzinga
News headline image
Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today ↗
Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share. 
Via Stocktwits
News headline image
Stock Market Today: Dow Jones, S&P 500 Futures Climb Ahead Of Busy Week On Wall Street—Novartis, Nucor, Waste Management In Focus ↗
U.S. stock futures rose on Monday following Friday’s positive moves. Futures of major benchmark indices were higher. 
Via Benzinga
Topics Stocks
News headline image
Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment
San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly... 
Via MarketMinute
News headline image
Jim Cramer: Time To 'Pull The Trigger' On Kratos, A 'Terrific' Stock ↗
Kratos secured a $68.3 million deal and a contract through the Defense Department's Industrial Base Analysis and Sustainment Program. 
Via Benzinga
News headline image
AI Revolutionizes Drug Discovery and Personalized Medicine: A New Era of Healthcare
The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence
News headline image
Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain ↗
Novartis' Cosentyx Phase 3 REPLENISH trial for polymyalgia rheumatica met primary and secondary endpoints, showing significant sustained remission. 
Via Benzinga
News headline image
Novartis AG-Sponsored ADR (NYSE:NVS): A Pillar of Dividend Reliability and Financial Health ↗
Novartis (NVS) offers a strong 3.35% dividend yield with a history of steady growth, backed by robust profitability and sound financial health for reliable income. 
Via Chartmill
News headline image
Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial ↗
Novartis' five-year NATALEE trial shows Kisqali plus endocrine therapy reduces recurrence risk and improves breast cancer survival. 
Via Benzinga
News headline image
Eli Lilly Makes A Bold Claim For Its Biggest Cancer Drug ↗
Eli Lilly said Friday a combo using Verzenio cut the risk of death by nearly 16% over two years for breast cancer patients. 
Via Investor's Business Daily
News headline image
AI: The Medical Maverick – Navigating Hype and Hope in Healthcare’s Digital Revolution
Artificial intelligence (AI) stands at the precipice of a profound transformation in healthcare, promising a future where diagnostics are sharper, treatments are more personalized, and patient care is... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline. 
Via Benzinga
News headline image
Novartis Strengthens Kidney Disease Pipeline With Promising Data ↗
Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026. 
Via Benzinga
News headline image
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Value Investors ↗
Novartis (NVS) is a financially sound pharma leader trading at an attractive valuation with strong profitability and steady growth. 
Via Chartmill
News headline image
Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears ↗
Telitacicept showed strong efficacy and safety in a 48-week Phase 3 trial for Sjögren's disease, meeting all primary and secondary endpoints. 
Via Benzinga
News headline image
Cogent Biosciences Soars to 52-Week High on "Breakthrough" Systemic Mastocytosis Trial Results
Cogent Biosciences (NASDAQ: COGT) experienced a dramatic surge in its stock price, hitting a 52-week high in early July 2025, following the announcement of highly positive "breakthrough results" from... 
Via MarketMinute
Topics Economy Supply Chain
News headline image
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest? ↗
Now may be the time to invest in drug companies, as they just slipped the tariff noose. 
Via The Motley Fool
Topics ETFs Government World Trade
News headline image
JPMorgan Elevates Incyte Price Target Amidst Robust Pipeline and Commercial Success, Yet Maintains Cautious "Neutral" Stance
JPMorgan Chase & Co. (NYSE: JPM) has recently recalibrated its outlook on the biopharmaceutical giant Incyte Corporation (NASDAQ: INCY), with a notable upward revision of its price target for the... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by... 
Via MarketMinute
News headline image
Cullen Capital Dumps 40% of BCE Holdings ↗
Via The Motley Fool
News headline image
AI Unlocks Secrets of Intrinsically Disordered Proteins: A Paradigm Shift in Biomedical Design
A groundbreaking advancement in artificial intelligence has opened new frontiers in understanding and designing intrinsically disordered proteins (IDPs), a class of biomolecules previously considered... 
Via TokenRing AI
Topics Artificial Intelligence Derivatives
News headline image
European Markets Soar: Healthcare and Mining Lead the Charge Amidst Dovish Fed and Robust Fundamentals
European financial markets are currently experiencing a period of remarkable strength, with major indices reaching or nearing all-time highs in early October 2025. This significant rally is largely... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
News headline image
2 Surefire Dividend Stocks to Buy for the Long Haul ↗
Both have crushed the market in 2025. 
Via The Motley Fool
Topics Economy Government Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today